tiprankstipranks
Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
US Market
IPHYF
Innate Pharma SA
RESEARCH TOOLSreports

Innate Pharma SA (IPHYF) Income Statement

27 Followers

Innate Pharma SA Income Statement

Last quarter (Q4 2025), Innate Pharma SA's total revenue was €-2.07M, a decrease of -109.67% from the same quarter last year. In Q4, Innate Pharma SA's net income was €-27.83M. See Innate Pharma SA’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
€ 2.79M€ 12.62M€ 51.90M€ 49.64M€ 12.11M
Gross Profit
€ 2.79M€ -31.86M€ 5.62M€ 6.01M€ -34.89M
Operating Expenses
€ 56.21M€ 19.72M€ 18.29M€ 63.44M€ 25.52M
Depreciation and Amortization
€ 1.38M€ 1.99M€ 5.09M€ 4.42M€ 4.60M
EBITDA
€ -58.84M€ -50.99M€ -1.84M€ -61.30M€ -43.23M
Operating Income
€ -57.36M€ -51.58M€ -12.67M€ -24.63M€ -47.83M
Other Income/Expenses
€ 1.98M€ 2.10M€ 5.10M€ -547.00K€ 2.35M
Pretax Income
€ -55.38M€ -56.96M€ -7.57M€ -57.97M€ -45.48M
Net Income
€ -49.18M€ -49.47M€ -7.57M€ -58.10M€ -52.81M
Per Share Metrics
Basic EPS
€ -0.55€ -0.61€ -0.09€ -0.73€ -0.74
Diluted EPS
€ -0.55€ -0.61€ -0.09€ -0.73€ -0.66
Weighted Average Shares Outstanding
 89.41M 60.93M 60.93M 60.93M 60.93M
Weighted Average Shares Outstanding (Diluted)
 89.41M 81.05M 80.45M 79.64M 79.54M
Currency in EUR

Innate Pharma SA Earnings and Revenue History